Promoting health since 1898

1950

HENNIG ARZNEIMITTEL is placed under state supervision and is at risk of expropriation by the Russian occupying forces. Kurt Moschner decides to leave Berlin and rebuild the company in the Rhine-Main area.

1951

Kurt Moschner rebuilds the company in less than three years at a site in Flörsheim am Main. For the first time, medication is produced solely using chemical substances.

1982

An original preparation for treating vertigo of various origins is introduced and a broad portfolio of generic medicines developed.

1984

Helga Schleenhain takes over the company

After the death of Kurt Moschner, his daughter Helga Schleenhain takes over management of the company, together with her husband Wolfram Schleenhain. The existing product range is expanded to include a variety of generic medicines, with a focus on cardiovascular, metabolic, neurological and psychiatric indications. In light of increased contract manufacturing and development, accompanied by steady growth in staff numbers, numerous extensions and new buildings are added to the company premises.

2006

Holger and Dr Kai Schleenhain take over the company

The two sons, Holger Schleenhain and Dr Kai Schleenhain, assume management of the company. They continue to take products global and expand the product range to include a number of new launches and over-the-counter products. By this time, HENNIG ARZNEIMITTEL employs roughly 280 people. Production volume amounts to around 600 million tablets per year.

2012

The original preparation for treating vertigo of different origins celebrates its 30th birthday.

2014

HENNIG ARZNEIMITTEL receives the Axia Award for its strategies for ensuring long-term financial success.

2016

Holger Schleenhain and Dr Kai Schleenhain, previously managing shareholders, take on the shared role of managing director for the fourth-generation family company, HENNIG ARZNEIMITTEL. This completes the change to a new generation.